Pulmonary Hypertension
-
BME’s Merryman and collaborators find potential way to prevent rare lung disease
Research by Vanderbilt scientists suggests that it may be possible to prevent or even reverse pulmonary arterial hypertension (PAH), a rare, progressive disease characterized by narrowing of and high blood pressure in the small arteries of the lungs. A key player in PAH is the proangiogenic cell (PAC), a cell… Read MoreNov. 20, 2018
-
Merryman wins $6M to address heart disease with arthritis drug, fund other research
Associate Professor of Biomedical Engineering Dave Merryman interacting with a student in his lab. (Daniel Dubois / Vanderbilt University) A Vanderbilt biomedical engineering professor has garnered $6 million total in grants to determine how to treat heart valve disease, pulmonary hypertension and heart failure using drugs originally developed for rheumatoid arthritis… Read MoreFeb. 1, 2017